Dr. Jonathan Chou

Hope Rugo is an Oncologist practicing medicine in San Francisco, California. Dr. Rugo is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).

Dr. Julie Ann Sosa is an endocrine surgeon who specializes in thyroid cancer. She also has expertise in treating adults and children for a variety of benign and malignant endocrine conditions of the thyroid, parathyroid and adrenal glands. She chairs the UCSF Department of Surgery. Sosa's research focuses on developing treatments for advanced thyroid cancer and understanding environmental factors that can raise a person's risk for the disease. She also has published extensively on predictors of optimal patient outcomes following a variety of cancer-based procedures. Sosa earned her medical degree at Johns Hopkins University School of Medicine, where she also completed the Halsted residency in general surgery and served as chief resident. She completed a fellowship in clinical research with the Robert Wood Johnson Foundation at Johns Hopkins, where she was also assistant chief of service and an instructor. She has a master's degree in human sciences from the University of Oxford. Prior to joining UCSF, she was chief of endocrine surgery at Duke University, and held leadership positions at the Duke Cancer Institute and Duke Clinical Research Institute. Sosa is a fellow of the American College of Surgeons. She is the elected editor-in-chief of the World Journal of Surgery, and had previous positions as deputy editor of JAMA Surgery and associate editor of the Journal of Surgical Research. She serves on the editorial boards of seven medical journals, including the Annals of Surgery, Surgery, Annals of Surgical Oncology, Endocrine and International Journal of Endocrine Oncology. She serves on the boards of the Society of Surgical Oncology, International Thyroid Oncology Group, Association for Academic Surgery Foundation and American Thyroid Association, where she is also treasurer. She is the Leon Goldman, MD Distinguished Professor of Surgery at UCSF. Sosa was born in Montréal and raised in upstate New York. Dr. Sosa is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Thyroid Cancer, Papillary Thyroid Cancer, Parathyroid Hyperplasia, Thyroidectomy, and Parathyroidectomy. Dr. Sosa is board certified in American Board Of Surgery, General Surgery. Dr. Sosa is currently accepting new patients.

Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.